Novel ^sup 18^F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of ^sup 18^F-LY2459989 in Nonhuman Primates

The κ-opioid receptor (KOR) has been implicated in depression, addictions, and other central nervous system disorders and, thus, is an important target for drug development. We previously developed several 11C-labeled PET radiotracers for KOR imaging in humans. Here we report the synthesis and evalu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of nuclear medicine (1978) 2018-01, Vol.59 (1), p.140
Hauptverfasser: Li, Songye, Cai, Zhengxin, Zheng, Ming-Qiang, Holden, Daniel, Naganawa, Mika, Lin, Shu-Fei, Ropchan, Jim, Labaree, David, Kapinos, Michael, Lara-Jaime, Teresa, Navarro, Antonio, Huang, Yiyun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 140
container_title The Journal of nuclear medicine (1978)
container_volume 59
creator Li, Songye
Cai, Zhengxin
Zheng, Ming-Qiang
Holden, Daniel
Naganawa, Mika
Lin, Shu-Fei
Ropchan, Jim
Labaree, David
Kapinos, Michael
Lara-Jaime, Teresa
Navarro, Antonio
Huang, Yiyun
description The κ-opioid receptor (KOR) has been implicated in depression, addictions, and other central nervous system disorders and, thus, is an important target for drug development. We previously developed several 11C-labeled PET radiotracers for KOR imaging in humans. Here we report the synthesis and evaluation of 18F-LY2459989 as the first 18F-labeled KOR antagonist radiotracer in nonhuman primates and its comparison with 11C-LY2459989. Methods: The novel radioligand 18F-LY2459989 was synthesized by 18F displacement of a nitro group or an iodonium ylide. PET scans in rhesus monkeys were obtained on a small-animal scanner to assess the pharmacokinetic and in vivo binding properties of the ligand. Metabolite-corrected arterial activity curves were measured and used as input functions in the analysis of brain time-activity curves and the calculation of binding parameters. Results: With the iodonium ylide precursor, 18F-LY2459989 was prepared at high radiochemical yield (36% ± 7% [mean ± SD]), radiochemical purity (>99%), and mean molar activity (1,175 GBq/µmol; n = 6). In monkeys, 18F-LY2459989 was metabolized at a moderate rate, with a parent fraction of approximately 35% at 30 min after injection. Fast and reversible kinetics were observed, with a regional peak uptake time of less than 20 min. Pretreatment with the selective KOR antagonist LY2456302 (0.1 mg/kg) decreased the activity level in regions with high levels of binding to that in the cerebellum, thus demonstrating the binding specificity and selectivity of 18F-LY2459989 in vivo. Regional time-activity curves were well fitted by the multilinear analysis 1 kinetic model to derive reliable estimates of regional distribution volumes. With the cerebellum as the reference region, regional binding potentials were calculated and ranked as follows: cingulate cortex > insula > caudate/putamen > frontal cortex > temporal cortex > thalamus, consistent with the reported KOR distribution in the monkey brain. Conclusion: The evaluation of 18F-LY2459989 in nonhuman primates demonstrated many attractive imaging properties: fast tissue kinetics, specific and selective binding to the KOR, and high specific binding signals. A side-by-side comparison of 18F-LY2459989 and 11C-LY2459989 indicated similar kinetic and binding profiles for the 2 radiotracers. Taken together, the results indicated that 18F-LY2459989 appears to be an excellent PET radiotracer for the imaging and quantification of the KOR in vivo.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1993353061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1993353061</sourcerecordid><originalsourceid>FETCH-proquest_journals_19933530613</originalsourceid><addsrcrecordid>eNqNjU1KAzEYQIMoOFbv8IHrQGJMzLgTmaIgtbRFcNPy2UltyjTfmJ8BL-JhPIRn0oULl67e4j14B6ySWmmujbk6ZJWQRnKthT5mJynthBDGWluxjwkNroNlKj1IuxzzB3xxnWvh65M_9p58CzO3dn2mCDch4ysFnzJggmmzgBm2nnLEtYvXMH8PeeuST4ChhfsAT34gaAbsCmZPAWjz9_N8canr2tbgA0wobMseA0yj32N26ZQdbbBL7uyXI3Y-bha3d7yP9FZcyqsdlRh-1ErWtVJaCSPV_6pvzgdXRw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1993353061</pqid></control><display><type>article</type><title>Novel ^sup 18^F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of ^sup 18^F-LY2459989 in Nonhuman Primates</title><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Li, Songye ; Cai, Zhengxin ; Zheng, Ming-Qiang ; Holden, Daniel ; Naganawa, Mika ; Lin, Shu-Fei ; Ropchan, Jim ; Labaree, David ; Kapinos, Michael ; Lara-Jaime, Teresa ; Navarro, Antonio ; Huang, Yiyun</creator><creatorcontrib>Li, Songye ; Cai, Zhengxin ; Zheng, Ming-Qiang ; Holden, Daniel ; Naganawa, Mika ; Lin, Shu-Fei ; Ropchan, Jim ; Labaree, David ; Kapinos, Michael ; Lara-Jaime, Teresa ; Navarro, Antonio ; Huang, Yiyun</creatorcontrib><description>The κ-opioid receptor (KOR) has been implicated in depression, addictions, and other central nervous system disorders and, thus, is an important target for drug development. We previously developed several 11C-labeled PET radiotracers for KOR imaging in humans. Here we report the synthesis and evaluation of 18F-LY2459989 as the first 18F-labeled KOR antagonist radiotracer in nonhuman primates and its comparison with 11C-LY2459989. Methods: The novel radioligand 18F-LY2459989 was synthesized by 18F displacement of a nitro group or an iodonium ylide. PET scans in rhesus monkeys were obtained on a small-animal scanner to assess the pharmacokinetic and in vivo binding properties of the ligand. Metabolite-corrected arterial activity curves were measured and used as input functions in the analysis of brain time-activity curves and the calculation of binding parameters. Results: With the iodonium ylide precursor, 18F-LY2459989 was prepared at high radiochemical yield (36% ± 7% [mean ± SD]), radiochemical purity (&gt;99%), and mean molar activity (1,175 GBq/µmol; n = 6). In monkeys, 18F-LY2459989 was metabolized at a moderate rate, with a parent fraction of approximately 35% at 30 min after injection. Fast and reversible kinetics were observed, with a regional peak uptake time of less than 20 min. Pretreatment with the selective KOR antagonist LY2456302 (0.1 mg/kg) decreased the activity level in regions with high levels of binding to that in the cerebellum, thus demonstrating the binding specificity and selectivity of 18F-LY2459989 in vivo. Regional time-activity curves were well fitted by the multilinear analysis 1 kinetic model to derive reliable estimates of regional distribution volumes. With the cerebellum as the reference region, regional binding potentials were calculated and ranked as follows: cingulate cortex &gt; insula &gt; caudate/putamen &gt; frontal cortex &gt; temporal cortex &gt; thalamus, consistent with the reported KOR distribution in the monkey brain. Conclusion: The evaluation of 18F-LY2459989 in nonhuman primates demonstrated many attractive imaging properties: fast tissue kinetics, specific and selective binding to the KOR, and high specific binding signals. A side-by-side comparison of 18F-LY2459989 and 11C-LY2459989 indicated similar kinetic and binding profiles for the 2 radiotracers. Taken together, the results indicated that 18F-LY2459989 appears to be an excellent PET radiotracer for the imaging and quantification of the KOR in vivo.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><language>eng</language><publisher>New York: Society of Nuclear Medicine</publisher><subject>Antagonist drugs ; Brain ; Central nervous system ; Cerebellum ; Cortex (cingulate) ; Cortex (frontal) ; Drug development ; Evaluation ; Imaging ; Kinetics ; Mental depression ; Monkeys ; Narcotics ; Neuroimaging ; Opioid receptors ; Pharmacology ; Positron emission ; Positron emission tomography ; Primates ; Putamen ; Radiochemical analysis ; Selective binding ; Synthesis ; Temporal lobe ; Thalamus ; Tomography</subject><ispartof>The Journal of nuclear medicine (1978), 2018-01, Vol.59 (1), p.140</ispartof><rights>Copyright Society of Nuclear Medicine Jan 1, 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Li, Songye</creatorcontrib><creatorcontrib>Cai, Zhengxin</creatorcontrib><creatorcontrib>Zheng, Ming-Qiang</creatorcontrib><creatorcontrib>Holden, Daniel</creatorcontrib><creatorcontrib>Naganawa, Mika</creatorcontrib><creatorcontrib>Lin, Shu-Fei</creatorcontrib><creatorcontrib>Ropchan, Jim</creatorcontrib><creatorcontrib>Labaree, David</creatorcontrib><creatorcontrib>Kapinos, Michael</creatorcontrib><creatorcontrib>Lara-Jaime, Teresa</creatorcontrib><creatorcontrib>Navarro, Antonio</creatorcontrib><creatorcontrib>Huang, Yiyun</creatorcontrib><title>Novel ^sup 18^F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of ^sup 18^F-LY2459989 in Nonhuman Primates</title><title>The Journal of nuclear medicine (1978)</title><description>The κ-opioid receptor (KOR) has been implicated in depression, addictions, and other central nervous system disorders and, thus, is an important target for drug development. We previously developed several 11C-labeled PET radiotracers for KOR imaging in humans. Here we report the synthesis and evaluation of 18F-LY2459989 as the first 18F-labeled KOR antagonist radiotracer in nonhuman primates and its comparison with 11C-LY2459989. Methods: The novel radioligand 18F-LY2459989 was synthesized by 18F displacement of a nitro group or an iodonium ylide. PET scans in rhesus monkeys were obtained on a small-animal scanner to assess the pharmacokinetic and in vivo binding properties of the ligand. Metabolite-corrected arterial activity curves were measured and used as input functions in the analysis of brain time-activity curves and the calculation of binding parameters. Results: With the iodonium ylide precursor, 18F-LY2459989 was prepared at high radiochemical yield (36% ± 7% [mean ± SD]), radiochemical purity (&gt;99%), and mean molar activity (1,175 GBq/µmol; n = 6). In monkeys, 18F-LY2459989 was metabolized at a moderate rate, with a parent fraction of approximately 35% at 30 min after injection. Fast and reversible kinetics were observed, with a regional peak uptake time of less than 20 min. Pretreatment with the selective KOR antagonist LY2456302 (0.1 mg/kg) decreased the activity level in regions with high levels of binding to that in the cerebellum, thus demonstrating the binding specificity and selectivity of 18F-LY2459989 in vivo. Regional time-activity curves were well fitted by the multilinear analysis 1 kinetic model to derive reliable estimates of regional distribution volumes. With the cerebellum as the reference region, regional binding potentials were calculated and ranked as follows: cingulate cortex &gt; insula &gt; caudate/putamen &gt; frontal cortex &gt; temporal cortex &gt; thalamus, consistent with the reported KOR distribution in the monkey brain. Conclusion: The evaluation of 18F-LY2459989 in nonhuman primates demonstrated many attractive imaging properties: fast tissue kinetics, specific and selective binding to the KOR, and high specific binding signals. A side-by-side comparison of 18F-LY2459989 and 11C-LY2459989 indicated similar kinetic and binding profiles for the 2 radiotracers. Taken together, the results indicated that 18F-LY2459989 appears to be an excellent PET radiotracer for the imaging and quantification of the KOR in vivo.</description><subject>Antagonist drugs</subject><subject>Brain</subject><subject>Central nervous system</subject><subject>Cerebellum</subject><subject>Cortex (cingulate)</subject><subject>Cortex (frontal)</subject><subject>Drug development</subject><subject>Evaluation</subject><subject>Imaging</subject><subject>Kinetics</subject><subject>Mental depression</subject><subject>Monkeys</subject><subject>Narcotics</subject><subject>Neuroimaging</subject><subject>Opioid receptors</subject><subject>Pharmacology</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Primates</subject><subject>Putamen</subject><subject>Radiochemical analysis</subject><subject>Selective binding</subject><subject>Synthesis</subject><subject>Temporal lobe</subject><subject>Thalamus</subject><subject>Tomography</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNjU1KAzEYQIMoOFbv8IHrQGJMzLgTmaIgtbRFcNPy2UltyjTfmJ8BL-JhPIRn0oULl67e4j14B6ySWmmujbk6ZJWQRnKthT5mJynthBDGWluxjwkNroNlKj1IuxzzB3xxnWvh65M_9p58CzO3dn2mCDch4ysFnzJggmmzgBm2nnLEtYvXMH8PeeuST4ChhfsAT34gaAbsCmZPAWjz9_N8canr2tbgA0wobMseA0yj32N26ZQdbbBL7uyXI3Y-bha3d7yP9FZcyqsdlRh-1ErWtVJaCSPV_6pvzgdXRw</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Li, Songye</creator><creator>Cai, Zhengxin</creator><creator>Zheng, Ming-Qiang</creator><creator>Holden, Daniel</creator><creator>Naganawa, Mika</creator><creator>Lin, Shu-Fei</creator><creator>Ropchan, Jim</creator><creator>Labaree, David</creator><creator>Kapinos, Michael</creator><creator>Lara-Jaime, Teresa</creator><creator>Navarro, Antonio</creator><creator>Huang, Yiyun</creator><general>Society of Nuclear Medicine</general><scope>4T-</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>20180101</creationdate><title>Novel ^sup 18^F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of ^sup 18^F-LY2459989 in Nonhuman Primates</title><author>Li, Songye ; Cai, Zhengxin ; Zheng, Ming-Qiang ; Holden, Daniel ; Naganawa, Mika ; Lin, Shu-Fei ; Ropchan, Jim ; Labaree, David ; Kapinos, Michael ; Lara-Jaime, Teresa ; Navarro, Antonio ; Huang, Yiyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19933530613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antagonist drugs</topic><topic>Brain</topic><topic>Central nervous system</topic><topic>Cerebellum</topic><topic>Cortex (cingulate)</topic><topic>Cortex (frontal)</topic><topic>Drug development</topic><topic>Evaluation</topic><topic>Imaging</topic><topic>Kinetics</topic><topic>Mental depression</topic><topic>Monkeys</topic><topic>Narcotics</topic><topic>Neuroimaging</topic><topic>Opioid receptors</topic><topic>Pharmacology</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Primates</topic><topic>Putamen</topic><topic>Radiochemical analysis</topic><topic>Selective binding</topic><topic>Synthesis</topic><topic>Temporal lobe</topic><topic>Thalamus</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Songye</creatorcontrib><creatorcontrib>Cai, Zhengxin</creatorcontrib><creatorcontrib>Zheng, Ming-Qiang</creatorcontrib><creatorcontrib>Holden, Daniel</creatorcontrib><creatorcontrib>Naganawa, Mika</creatorcontrib><creatorcontrib>Lin, Shu-Fei</creatorcontrib><creatorcontrib>Ropchan, Jim</creatorcontrib><creatorcontrib>Labaree, David</creatorcontrib><creatorcontrib>Kapinos, Michael</creatorcontrib><creatorcontrib>Lara-Jaime, Teresa</creatorcontrib><creatorcontrib>Navarro, Antonio</creatorcontrib><creatorcontrib>Huang, Yiyun</creatorcontrib><collection>Docstoc</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Songye</au><au>Cai, Zhengxin</au><au>Zheng, Ming-Qiang</au><au>Holden, Daniel</au><au>Naganawa, Mika</au><au>Lin, Shu-Fei</au><au>Ropchan, Jim</au><au>Labaree, David</au><au>Kapinos, Michael</au><au>Lara-Jaime, Teresa</au><au>Navarro, Antonio</au><au>Huang, Yiyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel ^sup 18^F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of ^sup 18^F-LY2459989 in Nonhuman Primates</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><date>2018-01-01</date><risdate>2018</risdate><volume>59</volume><issue>1</issue><spage>140</spage><pages>140-</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><abstract>The κ-opioid receptor (KOR) has been implicated in depression, addictions, and other central nervous system disorders and, thus, is an important target for drug development. We previously developed several 11C-labeled PET radiotracers for KOR imaging in humans. Here we report the synthesis and evaluation of 18F-LY2459989 as the first 18F-labeled KOR antagonist radiotracer in nonhuman primates and its comparison with 11C-LY2459989. Methods: The novel radioligand 18F-LY2459989 was synthesized by 18F displacement of a nitro group or an iodonium ylide. PET scans in rhesus monkeys were obtained on a small-animal scanner to assess the pharmacokinetic and in vivo binding properties of the ligand. Metabolite-corrected arterial activity curves were measured and used as input functions in the analysis of brain time-activity curves and the calculation of binding parameters. Results: With the iodonium ylide precursor, 18F-LY2459989 was prepared at high radiochemical yield (36% ± 7% [mean ± SD]), radiochemical purity (&gt;99%), and mean molar activity (1,175 GBq/µmol; n = 6). In monkeys, 18F-LY2459989 was metabolized at a moderate rate, with a parent fraction of approximately 35% at 30 min after injection. Fast and reversible kinetics were observed, with a regional peak uptake time of less than 20 min. Pretreatment with the selective KOR antagonist LY2456302 (0.1 mg/kg) decreased the activity level in regions with high levels of binding to that in the cerebellum, thus demonstrating the binding specificity and selectivity of 18F-LY2459989 in vivo. Regional time-activity curves were well fitted by the multilinear analysis 1 kinetic model to derive reliable estimates of regional distribution volumes. With the cerebellum as the reference region, regional binding potentials were calculated and ranked as follows: cingulate cortex &gt; insula &gt; caudate/putamen &gt; frontal cortex &gt; temporal cortex &gt; thalamus, consistent with the reported KOR distribution in the monkey brain. Conclusion: The evaluation of 18F-LY2459989 in nonhuman primates demonstrated many attractive imaging properties: fast tissue kinetics, specific and selective binding to the KOR, and high specific binding signals. A side-by-side comparison of 18F-LY2459989 and 11C-LY2459989 indicated similar kinetic and binding profiles for the 2 radiotracers. Taken together, the results indicated that 18F-LY2459989 appears to be an excellent PET radiotracer for the imaging and quantification of the KOR in vivo.</abstract><cop>New York</cop><pub>Society of Nuclear Medicine</pub></addata></record>
fulltext fulltext
identifier ISSN: 0161-5505
ispartof The Journal of nuclear medicine (1978), 2018-01, Vol.59 (1), p.140
issn 0161-5505
1535-5667
language eng
recordid cdi_proquest_journals_1993353061
source Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Antagonist drugs
Brain
Central nervous system
Cerebellum
Cortex (cingulate)
Cortex (frontal)
Drug development
Evaluation
Imaging
Kinetics
Mental depression
Monkeys
Narcotics
Neuroimaging
Opioid receptors
Pharmacology
Positron emission
Positron emission tomography
Primates
Putamen
Radiochemical analysis
Selective binding
Synthesis
Temporal lobe
Thalamus
Tomography
title Novel ^sup 18^F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of ^sup 18^F-LY2459989 in Nonhuman Primates
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T21%3A06%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20%5Esup%2018%5EF-Labeled%20%CE%BA-Opioid%20Receptor%20Antagonist%20as%20PET%20Radiotracer:%20Synthesis%20and%20In%20Vivo%20Evaluation%20of%20%5Esup%2018%5EF-LY2459989%20in%20Nonhuman%20Primates&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Li,%20Songye&rft.date=2018-01-01&rft.volume=59&rft.issue=1&rft.spage=140&rft.pages=140-&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/&rft_dat=%3Cproquest%3E1993353061%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1993353061&rft_id=info:pmid/&rfr_iscdi=true